Private Equity

AES secures crucial bondholder consent, advancing its massive acquisition by GIP and EQT and signaling a major strategic shift in the energy sector.

In a tough biotech market, NewcelX's $1.35M financing at a 30% premium signals strong confidence in its pioneering stem cell therapy for Type 1 Diabetes.

Veteran biotech CEO Paul Sekhri joins investor Petrichor, signaling a strategic shift where hands-on leadership is now paramount in life sciences investing.

After 11 straight quarters of growth, clean nail care pioneer MiniLuxe lands new funding. Discover how its tech-driven, ethical model is winning.

A new data-rich platform aims to help advisors navigate the booming private markets by providing unprecedented transparency and analytical tools.

Arclin completes its acquisition of DuPont's iconic Aramids business, a transformational move that repositions the company and marks a new era for Kevlar and Nomex.

FitLife Brands' massive revenue growth from its Irwin Naturals acquisition masks declining profits and legacy brand struggles, forcing a strategic pivot.

Securus Technologies is turning prisons into talent pipelines, but its controversial past casts a long shadow over this ambitious workforce initiative.

The wealth giant's acquisition of Vantage Financial Partners adds nearly $1B in AUM, signaling a strategic push into new markets and a bet on its holistic model.

With record-high lithium concentrations and new funding, Barrell Energy is scaling up its East Texas operations, fueling America's energy independence race.

Celebrating 50 years, L'Occitane en Provence balances its rich heritage with global growth, B Corp-certified sustainability, and immersive retail.

Metals developer Serval Resources launches an AIM IPO and retail offer, banking on African copper projects to power the global green energy transition.

The energy firm's new agreement with Bahiagás boosts sales by 25% and fuels record production, signaling a profitable future in Brazil's evolving market.

A new ultra-low fee for large deals challenges traditional brokers and signals a digital revolution in the multi-billion dollar secondary market.

Investors eye Alaska Air Group's Q1 results for insights on the Hawaiian Airlines integration, rising fuel costs, and shifting travel demand.

The biopharma firm touts transformative drug data ahead, but with cash for only month-to-month operations, its future hangs by a precarious thread.

The luxury brand missed Q4 estimates, citing market challenges, but CEO Gary Friedman laid out a bold, multi-year path for global expansion and growth.

With FDA approval, soaring revenues, and game-changing clinical data, InspireMD prepares to spotlight its CGuard Prime stent for investors this April.

The carbon-tech firm slashes losses and touts a key SAF partnership, but dwindling cash reserves raise questions about its path to sustainable growth.

Investors in distressed Ravelin Properties REIT are forming a group to scrutinize a $1.1B rescue deal, signaling a potential battle over its fairness.